Your Cart

Imagion Biosystems receives AU$3.5 million in R&D tax incentives

Imagion Biosystems receives AU$3.5 million in R&D tax incentives

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it has received its 2022 R&D tax incentive claim of $3,534,712 from the Australian Taxation Office.

This is materially higher than the $2,500,966 received in respect of the 2021 claim and reflects an increased level of R&D spend in 2022.

— ENDS —

View PDF version of the announcement

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For more information, visit

Imagion Biosystems Interactive Investor Hub

Engage with us directly by asking questions, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub:

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.